VEGF-C D2-40 E-Cad在乳腺癌中的表达及意义

Expression and Significance of VEGF-C, D2-40, and E-Cad in Human Breast Carcinoma

目的:探讨VEGF-C、D2-40、E-Cad在乳腺癌中的表达及意义。方法:采用免疫组织化学方法,检测临床病理及随访资料完整的88例乳腺浸润性导管癌及54例导管内增生性病变组织中VEGF-C的表达情况,分析其与D2-40、E-Cad表达的关系及其临床病理意义.结果:VEGF-C在浸润癌组的阳性表达率显著性强于不典型增生组和普通型增生组;同时淋巴结转移组显著性强于无淋巴结转移组;乳腺癌变组LVD明显高于乳腺不典型增生组和普通型增生组,淋巴结转移阳性组LVD计数明显高于淋巴结转移阴性组;E-Cad在浸润癌组中的阳性表达率明显低于不典型增生组及普通型增生组,淋巴结转移组显著性低于无淋巴结转移组,VEGF-C与D2-40呈正相关,与E-Cad呈负相关。结论:VEGF-C与D2-40的联合检测可以作为临床评价肿瘤早期淋巴道转移的重要指标;VEGF-C与E-Cad的联合使用可作为乳腺癌预后的重要指标。

Objective： To study the expression and significance of VEGF-C, D2-40, and E-Cad in Human breast carcinoma. Methods： S-P immunohistochemical method was used to assess the expression of VEGF-C in 88 cases of infiltrating ductal carcinoma of the breast （with intact clinicopathologic and follow-up information） and 54 cases of different intraductal hyperplastic lesions. The relationship of VEGF-C expression with D2-40 and E-Cadherin in infiltrating ductal carcinoma of the breast was analyzed. Results： VEGF-C expression was higher in the invasive group than that in the dysplasia group and benign lesions. VEGF-C expression in the metastatic group was significantly higher than that in the group without lymph node metastasis, indicating that VEGF-C plays an important role in the growth and metastasis of breast cancer. VEGF expression in breast cancer group was higher than that in the dysplasia group and benign lesions. LVD count in the group with lymph node metastasis was significantly higher than that in the group without lymph node metastasis. The positive rate of E-Cad expression in the invasive group was significantly lower than that in the dysplasia group and benign lesions. VEGF-C expression was positively correlated with D2-40 expression. VEGF-C expression was negatively correlated with E-Cad expression. Conclusion： VEGF-C and D2-40 could be used for the detection of early lymphatic metastasis of breast cancer. VEGF-C and E-Cad can be used as important indices for the evaluation of the prognosis of breast cancer.